
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.
Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway Therapies
Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4.1
2525 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XJK865. CME credit will be available until February 25, 2026.
Advancements in IgA Nephropathy: Discovering the Potential of Complement Pathway Therapies
Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This accredited activity has been developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure information is available at the beginning of the video presentation.

43,543 Listeners

137 Listeners

320 Listeners

698 Listeners

497 Listeners

29 Listeners

11 Listeners

1,384 Listeners

5 Listeners

11 Listeners

3 Listeners

2 Listeners

5 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

11 Listeners

2 Listeners

882 Listeners

4 Listeners

3 Listeners

5 Listeners

3,347 Listeners

1,146 Listeners

193 Listeners

92 Listeners

515 Listeners

370 Listeners

426 Listeners